Gain Therapeutics announces Phase 1b clinical trial approval in Australia for GT-02287 to evaluate safety in Parkinson's disease patients. Gain Therapeutics, Inc. has received approval to start ...

Parkinson’s disease is the second most common neurological disease in Australia. As a degenerative disease with no known cure, managing and treating symptoms is vital, particularly when it comes to ...

Researchers based at Australia’s Translational Research Institute (TRI) have received major funding from the United States Department of Defense (DoD) to develop Parkinson’s disease (PD) treatments by ...

Scientists have finally pinned down a protein that’s largely responsible for Parkinson’s disease. Known as PINK1, the protein has been linked to the disease for decades but its structure and how to ...

Parkinson’s disease is a progressive disorder of later life, defined clinically by motor features (asymmetric bradykinesia, rigidity, tremor, and imbalance) and pathologically by neuronal degeneration ...

We are so obsessed with finding the cure to Parkinson’s and other chronic illnesses that research priorities often ignore the needs of those who, like me, will not live long enough to experience that ...

A massive nationwide study has linked long-term exposure to the industrial chemical trichloroethylene (TCE) with a higher risk of Parkinson’s disease in older adults. Researchers examined over 1.1 ...